Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peficitinib - Astellas Pharma

Drug Profile

Peficitinib - Astellas Pharma

Alternative Names: ASP-015K; ASP-015K hydrobromide; JNJ-54781532; Peficitinib hydrobromide - Astellas Pharma; Smyraf

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Class Adamantanes; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Transplant rejection; Ulcerative colitis

Most Recent Events

  • 13 Sep 2023 Menarini Asia Pacific in-licenses Peficitinib from Astellas Pharma for Rheumatoid arthritis in Taiwan
  • 13 Sep 2023 Astellas Pharma has patent protection for composition of matter for patent named 'Heterocyclic janus kinase 3 inhibitors' before September 2023
  • 31 Aug 2022 Preregistration for Rheumatoid arthritis in China (PO) (Astellas Pharma pipeline, November 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top